Drug intelligence / Profile preview

DF2211

Development stage: Preclinical
Lead developer: Dragonfly Therapeutics
Modality: T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

DF2211 is a preclinical-stage immune engager being developed by Dragonfly Therapeutics that targets the B-cell activating factor receptor (BAFFR). The drug is designed to recruit immune effector cells to selectively deplete BAFFR-expressing B cells, which are central to the pathogenesis of several autoimmune conditions. By harnessing the body's immune system to target and eliminate these specific B cells, DF2211 aims to provide a potent therapeutic option for B-cell-driven diseases. It is currently in preclinical development for the treatment of Sjogren's syndrome, Pemphigus Vulgaris (PV), Bullous Pemphigoid (BP), and Lupus Nephritis (LN).

Targets

TNFRSF13C (B-cell Activating Factor Receptor)

Beyond the preview

Go deeper on DF2211.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DF2211.

Explore the full profile